{"id":41136,"date":"2025-09-11T10:58:49","date_gmt":"2025-09-11T02:58:49","guid":{"rendered":"https:\/\/flcube.com\/?p=41136"},"modified":"2025-09-11T10:58:50","modified_gmt":"2025-09-11T02:58:50","slug":"betta-pharmaceuticals-secures-nmpa-approval-for-mcla%e2%80%91129-ensartinib-combination-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41136","title":{"rendered":"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors"},"content":{"rendered":"\n<p>China-based <strong>Betta Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/300558:SHE\">SHE: 300558<\/a>)<\/strong> announced that China\u2019s National Medical Products Administration (NMPA) has approved its clinical\u2011trial application for the bispecific antibody <strong>MCLA\u2011129<\/strong> in combination with the multi\u2011targeted kinase inhibitor <strong>ensartinib<\/strong> to treat patients with advanced solid tumors exhibiting MET amplification or overexpression.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-is-mcla-129\">What Is MCLA\u2011129?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bispecific antibody<\/strong> that simultaneously targets the <strong>epidermal growth factor receptor (EGFR)<\/strong> and <strong>mesenchymal\u2011epithelial transition factor (c\u2011Met)<\/strong>.<\/li>\n\n\n\n<li>Blocks both EGFR and c\u2011Met signaling pathways, curbing tumor growth and survival.<\/li>\n\n\n\n<li>Enhances <strong>antibody\u2011dependent cell\u2011mediated cytotoxicity (ADCC)<\/strong>, increasing tumor\u2011cell killing potential.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ensartinib-a-proven-multi-target-inhibitor\">Ensartinib: A Proven Multi\u2011Target Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Inhibits <strong>c\u2011Met, ALK, ROS\u20111, and additional kinases<\/strong>.<\/li>\n\n\n\n<li>Co\u2011developed by Betta and its subsidiary <strong>Xcovery Holdings, Inc.<\/strong><\/li>\n\n\n\n<li>First NMPA approval in 2020; now approved for two indications.<\/li>\n\n\n\n<li>Launched in the U.S. in Dec\u202f2024, marking the first globally marketed small\u2011molecule targeted lung\u2011cancer drug led by a Chinese company.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-the-combination-matters\">Why the Combination Matters<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Multi\u2011pathway synergy<\/strong><\/td><td>Simultaneous EGFR and c\u2011Met blockade plus kinase inhibition amplifies antitumor activity.<\/td><\/tr><tr><td><strong>Prolonged PFS<\/strong><\/td><td>Expected to extend progression\u2011free survival in MET\u2011positive solid\u2011tumor patients.<\/td><\/tr><tr><td><strong>Clinical advantage<\/strong><\/td><td>Only comparable product approved both in China and internationally is the EGFR\/c\u2011Met bispecific <strong>amivantamab<\/strong>.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase I\/II trials<\/strong> will commence in Q4\u202f2025 to evaluate safety, tolerability, and preliminary efficacy.<\/li>\n\n\n\n<li>Betta plans to explore additional tumor types and biomarker\u2011driven subpopulations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u6ce8\u5c04\u7528MCLA-129\u4e0e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u8054\u7528\u6cbb\u7597\u665a\u671f\u5b9e\u4f53\u7624\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u6ce8\u5c04\u7528MCLA-129\u4e0e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u8054\u7528\u6cbb\u7597\u665a\u671f\u5b9e\u4f53\u7624\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-66e6ae39-29ed-48c9-b72b-c129118ebeb2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u6ce8\u5c04\u7528MCLA-129\u4e0e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u8054\u7528\u6cbb\u7597\u665a\u671f\u5b9e\u4f53\u7624\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u6ce8\u5c04\u7528MCLA-129\u4e0e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u8054\u7528\u6cbb\u7597\u665a\u671f\u5b9e\u4f53\u7624\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u6ce8\u5c04\u7528MCLA-129\u4e0e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u8054\u7528\u6cbb\u7597\u665a\u671f\u5b9e\u4f53\u7624\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-66e6ae39-29ed-48c9-b72b-c129118ebeb2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Betta Pharmaceuticals (SHE: 300558) announced that China\u2019s National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41138,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[231,16,62,29,1030,33,2840],"class_list":["post-41136","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-betta-pharmaceuticals","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-she-300558","tag-tkis-egfr-vegf-btk-etc","tag-xcovery-holdings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Betta Pharmaceuticals (SHE: 300558) announced that China\u2019s National Medical Products Administration (NMPA) has approved its clinical\u2011trial application for the bispecific antibody MCLA\u2011129 in combination with the multi\u2011targeted kinase inhibitor ensartinib to treat patients with advanced solid tumors exhibiting MET amplification or overexpression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41136\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"China-based Betta Pharmaceuticals (SHE: 300558) announced that China\u2019s National Medical Products Administration (NMPA) has approved its clinical\u2011trial application for the bispecific antibody MCLA\u2011129 in combination with the multi\u2011targeted kinase inhibitor ensartinib to treat patients with advanced solid tumors exhibiting MET amplification or overexpression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41136\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-11T02:58:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-11T02:58:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\\\/Ensartinib Combination in Advanced Solid Tumors\",\"datePublished\":\"2025-09-11T02:58:49+00:00\",\"dateModified\":\"2025-09-11T02:58:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136\"},\"wordCount\":247,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1101.webp\",\"keywords\":[\"Betta Pharmaceuticals\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"SHE: 300558\",\"TKIs (EGFR VEGF BTK etc.)\",\"Xcovery Holdings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41136#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41136\",\"name\":\"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\\\/Ensartinib Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1101.webp\",\"datePublished\":\"2025-09-11T02:58:49+00:00\",\"dateModified\":\"2025-09-11T02:58:50+00:00\",\"description\":\"China-based Betta Pharmaceuticals (SHE: 300558) announced that China\u2019s National Medical Products Administration (NMPA) has approved its clinical\u2011trial application for the bispecific antibody MCLA\u2011129 in combination with the multi\u2011targeted kinase inhibitor ensartinib to treat patients with advanced solid tumors exhibiting MET amplification or overexpression.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41136\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\\\/Ensartinib Combination in Advanced Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41136#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\\\/Ensartinib Combination in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Betta Pharmaceuticals (SHE: 300558) announced that China\u2019s National Medical Products Administration (NMPA) has approved its clinical\u2011trial application for the bispecific antibody MCLA\u2011129 in combination with the multi\u2011targeted kinase inhibitor ensartinib to treat patients with advanced solid tumors exhibiting MET amplification or overexpression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41136","og_locale":"en_US","og_type":"article","og_title":"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors","og_description":"China-based Betta Pharmaceuticals (SHE: 300558) announced that China\u2019s National Medical Products Administration (NMPA) has approved its clinical\u2011trial application for the bispecific antibody MCLA\u2011129 in combination with the multi\u2011targeted kinase inhibitor ensartinib to treat patients with advanced solid tumors exhibiting MET amplification or overexpression.","og_url":"https:\/\/flcube.com\/?p=41136","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-11T02:58:49+00:00","article_modified_time":"2025-09-11T02:58:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41136#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41136"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors","datePublished":"2025-09-11T02:58:49+00:00","dateModified":"2025-09-11T02:58:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41136"},"wordCount":247,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41136#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1101.webp","keywords":["Betta Pharmaceuticals","Cancer","Clinical trial approval \/ initiation","Combination therapy","SHE: 300558","TKIs (EGFR VEGF BTK etc.)","Xcovery Holdings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41136#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41136","url":"https:\/\/flcube.com\/?p=41136","name":"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41136#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41136#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1101.webp","datePublished":"2025-09-11T02:58:49+00:00","dateModified":"2025-09-11T02:58:50+00:00","description":"China-based Betta Pharmaceuticals (SHE: 300558) announced that China\u2019s National Medical Products Administration (NMPA) has approved its clinical\u2011trial application for the bispecific antibody MCLA\u2011129 in combination with the multi\u2011targeted kinase inhibitor ensartinib to treat patients with advanced solid tumors exhibiting MET amplification or overexpression.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41136#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41136"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41136#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1101.webp","width":1080,"height":608,"caption":"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41136#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Betta Pharmaceuticals Secures NMPA Approval for MCLA\u2011129\/Ensartinib Combination in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41136"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41136\/revisions"}],"predecessor-version":[{"id":41139,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41136\/revisions\/41139"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41138"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}